{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:34:50Z","timestamp":1761824090716,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"MEXT\/JSPS KAKENHI","award":["16K08660"],"award-info":[{"award-number":["16K08660"]}]},{"name":"The Japanese Foundation for Multidisciplinary Treatment of Cancer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00520-019-04674-8","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T19:12:09Z","timestamp":1549480329000},"page":"3813-3822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Characteristics of adverse events of endocrine therapies among older patients with breast cancer"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-0791","authenticated-orcid":false,"given":"Naoko","family":"Honma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masujiro","family":"Makita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigehira","family":"Saji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetuo","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Horii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Futoshi","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"key":"4674_CR1","first-page":"3365s","volume":"42","author":"WR Miller","year":"1982","unstructured":"Miller WR, Hawkins RA, Forrest AP (1982) Significance of aromatase activity in human breast cancer. Cancer Res 42:3365s\u20133368s","journal-title":"Cancer Res"},{"key":"4674_CR2","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"M Dowsett","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thurlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386:1341\u20131352","journal-title":"Lancet"},{"key":"4674_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/pin.12326","volume":"65","author":"N Honma","year":"2015","unstructured":"Honma N, Hosoi T, Arai T, Takubo K (2015) Estrogen and cancers of the colorectum, breast, and lung in postmenopausal women. Pathol Int 65:451\u2013459","journal-title":"Pathol Int"},{"key":"4674_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1470-2045(08)70100-1","volume":"9","author":"R Kennelly","year":"2008","unstructured":"Kennelly R, Kavanagh DO, Hogan AM, Winter DC (2008) Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol 9:385\u2013391","journal-title":"Lancet Oncol"},{"key":"4674_CR5","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S0140-6736(76)92217-0","volume":"1","author":"R Lindsay","year":"1976","unstructured":"Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC (1976) Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1:1038\u20131041","journal-title":"Lancet"},{"key":"4674_CR6","first-page":"3913","volume":"82","author":"DF Skafar","year":"1997","unstructured":"Skafar DF, Xu R, Morales J, Ram J, Sowers JR (1997) Clinical review 91: female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab 82:3913\u20133918","journal-title":"J Clin Endocrinol Metab"},{"key":"4674_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0140-6736(96)03356-9","volume":"348","author":"MX Tang","year":"1996","unstructured":"Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R (1996) Effect of oestrogen during menopause on risk and age at onset of Alzheimer\u2019s disease. Lancet 348:429\u2013432","journal-title":"Lancet"},{"key":"4674_CR8","doi-asserted-by":"publisher","first-page":"726-017-00815-3","DOI":"10.1038\/s41598-017-00815-3","volume":"7","author":"N Honma","year":"2017","unstructured":"Honma N, Saji S, Mikami T, Yoshimura N, Mori S, Saito Y, Murayama S, Harada N (2017) Estrogen-related factors in the frontal lobe of Alzheimer\u2019s disease patients and importance of body mass index. Sci Rep 7:726-017-00815-3","journal-title":"Sci Rep"},{"key":"4674_CR9","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S1470-2045(15)00049-2","volume":"16","author":"J Bernhard","year":"2015","unstructured":"Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Puglisi F, Pavesi L, Parmar V, Regan MM, Pagani O, Fleming GF, Francis PA, Price KN, Coates AS, Gelber RD, Goldhirsch A, Walley BA (2015) Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol 16:848\u2013858","journal-title":"Lancet Oncol"},{"key":"4674_CR10","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1200\/JCO.1999.17.9.2659","volume":"17","author":"R Day","year":"1999","unstructured":"Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B (1999) Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17:2659\u20132669","journal-title":"J Clin Oncol"},{"key":"4674_CR11","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/jnci\/93.21.1615","volume":"93","author":"R Day","year":"2001","unstructured":"Day R, Ganz PA, Costantino JP (2001) Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project\u2019s Breast Cancer Prevention (P-1) Randomized Study. J Natl Cancer Inst 93:1615\u20131623","journal-title":"J Natl Cancer Inst"},{"key":"4674_CR12","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1200\/JCO.2004.08.029","volume":"22","author":"L Fallowfield","year":"2004","unstructured":"Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22:4261\u20134271","journal-title":"J Clin Oncol"},{"key":"4674_CR13","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.2005.03.3654","volume":"24","author":"LJ Fallowfield","year":"2006","unstructured":"Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, Hall E (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24:910\u2013917","journal-title":"J Clin Oncol"},{"key":"4674_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.amjsurg.2006.06.018","volume":"192","author":"JR Garreau","year":"2006","unstructured":"Garreau JR, Delamelena T, Walts D, Karamlou K, Johnson N (2006) Side effects of aromatase inhibitors versus tamoxifen: the patients\u2019 perspective. Am J Surg 192:496\u2013498","journal-title":"Am J Surg"},{"key":"4674_CR15","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1200\/JCO.2013.51.2483","volume":"32","author":"E Maunsell","year":"2014","unstructured":"Maunsell E, Goss PE, Chlebowski RT, Ingle JN, Ales-Martinez JE, Sarto GE, Fabian CJ, Pujol P, Ruiz A, Cooke AL, Hendrix S, Thayer DW, Rowland KM, Dube P, Spadafora S, Pruthi S, Lickley L, Ellard SL, Cheung AM, Wactawski-Wende J, Gelmon KA, Johnston D, Hiltz A, Brundage M, Pater JL, Tu D, Richardson H (2014) Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol 32:1427\u20131436","journal-title":"J Clin Oncol"},{"key":"4674_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-319-16366-6_3","volume":"862","author":"A Hurria","year":"2015","unstructured":"Hurria A, Muss H (2015) Special issues in older women with breast cancer. Adv Exp Med Biol 862:23\u201337","journal-title":"Adv Exp Med Biol"},{"key":"4674_CR17","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1200\/JCO.2007.12.6334","volume":"26","author":"HB Muss","year":"2008","unstructured":"Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE (2008) Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 26:1956\u20131964","journal-title":"J Clin Oncol"},{"key":"4674_CR18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/bjs.8743","volume":"99","author":"W Water van de","year":"2012","unstructured":"van de Water W, Bastiaannet E, Dekkers OM, de Craen AJ, Westendorp RG, Voogd AC, van de Velde CJ, Liefers GJ (2012) Adherence to treatment guidelines and survival in patients with early-stage breast cancer by age at diagnosis. Br J Surg 99:813\u2013820","journal-title":"Br J Surg"},{"key":"4674_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1634\/theoncologist.2011-0037","volume":"17","author":"W Water van de","year":"2012","unstructured":"van de Water W, Bastiaannet E, Hille ET, Meershoek-Klein Kranenbarg EM, Putter H, Seynaeve CM, Paridaens R, de Craen AJ, Westendorp RG, Liefers GJ, van de Velde CJ (2012) Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis. Oncologist 17:55\u201363","journal-title":"Oncologist"},{"key":"4674_CR20","first-page":"590","volume":"307","author":"W Water van de","year":"2012","unstructured":"van de Water W, Markopoulos C, van de Velde CJ, Seynaeve C, Hasenburg A, Rea D, Putter H, Nortier JW, de Craen AJ, Hille ET, Bastiaannet E, Hadji P, Westendorp RG, Liefers GJ, Jones SE (2012) Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA 307:590\u2013597","journal-title":"JAMA"},{"key":"4674_CR21","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","volume":"28","author":"G Curigliano","year":"2017","unstructured":"Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn H, Thurlimann B, St Gallen Int Expert Consensus (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 28:1700\u20131712","journal-title":"Ann Oncol"},{"key":"4674_CR22","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1111\/j.1349-7006.2011.02018.x","volume":"102","author":"N Honma","year":"2011","unstructured":"Honma N, Saji S, Hirose M, Horiguchi S, Kuroi K, Hayashi S, Utsumi T, Harada N (2011) Sex steroid hormones in pairs of tumor and serum from breast cancer patients and pathobiological role of androstene-3beta, 17beta-diol. Cancer Sci 102:1848\u20131854","journal-title":"Cancer Sci"},{"key":"4674_CR23","first-page":"104","volume":"34-0601 Tr 23","author":"S Saji","year":"2012","unstructured":"Saji S, Takada M, Honma N, Masuda N, Yamamoto Y, Kuroi K, Yamashita H, Ohno S, Ueno T, Toi M (2012) Serum concentration of estrone (E1), not estradiol (E2), is the independent predictive factor of response to neo-adjuvant exemestane treatment in postmenopausal. Breast Cancer Patients: Jfmc 34-0601 Tr 23:104\u2013104","journal-title":"Breast Cancer Patients: Jfmc"},{"key":"4674_CR24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1210\/endo.138.3.4979","volume":"138","author":"GG Kuiper","year":"1997","unstructured":"Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138:863\u2013870","journal-title":"Endocrinology"},{"key":"4674_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0014-5793(97)00413-4","volume":"410","author":"GG Kuiper","year":"1997","unstructured":"Kuiper GG, Gustafsson JA (1997) The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 410:87\u201390","journal-title":"FEBS Lett"},{"key":"4674_CR26","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1210\/endo.139.10.6216","volume":"139","author":"GG Kuiper","year":"1998","unstructured":"Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139:4252\u20134263","journal-title":"Endocrinology"},{"key":"4674_CR27","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1210\/en.2006-0113","volume":"147","author":"BT Zhu","year":"2006","unstructured":"Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR (2006) Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: insights into the structural determinants favoring a differential subtype binding. Endocrinology 147:4132\u20134150","journal-title":"Endocrinology"},{"key":"4674_CR28","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1126\/science.277.5331.1508","volume":"277","author":"K Paech","year":"1997","unstructured":"Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS (1997) Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277:1508\u20131510","journal-title":"Science"},{"key":"4674_CR29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0736-5748(99)00097-0","volume":"18","author":"H Shy","year":"2000","unstructured":"Shy H, Malaiyandi L, Timiras PS (2000) Protective action of 17beta-estradiol and tamoxifen on glutamate toxicity in glial cells. Int J Dev Neurosci 18:289\u2013297","journal-title":"Int J Dev Neurosci"},{"key":"4674_CR30","first-page":"9561968","volume":"2016","author":"B Torre Valdovinos de la","year":"2016","unstructured":"de la Torre Valdovinos B, Duenas Jimenez JM, Estrada IJ, Banuelos Pineda J, Franco Rodriguez NE, Lopez Ruiz JR, Osuna Carrasco LP, Candanedo Arellano A, Duenas Jimenez SH (2016) Tamoxifen promotes axonal preservation and gait locomotion recovery after spinal cord injury in cats. J Vet Med 2016:9561968","journal-title":"J Vet Med"},{"key":"4674_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2008.01.080","volume":"1204","author":"K Sharma","year":"2008","unstructured":"Sharma K, Mehra RD (2008) Long-term administration of estrogen or tamoxifen to ovariectomized rats affords neuroprotection to hippocampal neurons by modulating the expression of Bcl-2 and Bax. Brain Res 1204:1\u201315","journal-title":"Brain Res"},{"key":"4674_CR32","doi-asserted-by":"publisher","first-page":"bcr0620103089","DOI":"10.1136\/bcr.06.2010.3089","volume":"2010","author":"S Williams","year":"2010","unstructured":"Williams S, Michael B, Mewar D, Tunn E (2010) Inflammatory osteoarthritis which was precipitated by Arimidex and resolved with tamoxifen. BMJ Case Rep 2010:bcr0620103089. \n                    https:\/\/doi.org\/10.1136\/bcr.06.2010.3089","journal-title":"BMJ Case Rep"},{"key":"4674_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3793\/jaam.8.69","volume":"8","author":"N Keitaro","year":"2011","unstructured":"Keitaro N, Seizaburo A, Yoshikazu Y (2011) Development of a model of functional endocrine age in Japanese people\u2014serum dehydroepiandrosterone-sulfate (DHEA-s) concentration as an index of aging. Anti-Aging Med 8:69\u201374","journal-title":"Anti-Aging Med"},{"key":"4674_CR34","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/jama.285.7.885","volume":"285","author":"R Yancik","year":"2001","unstructured":"Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885\u2013892","journal-title":"JAMA"},{"key":"4674_CR35","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","volume":"7","author":"E Basch","year":"2006","unstructured":"Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903\u2013909","journal-title":"Lancet Oncol"},{"key":"4674_CR36","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJMp0911494","volume":"362","author":"E Basch","year":"2010","unstructured":"Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362:865\u2013869","journal-title":"N Engl J Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-04674-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04674-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04674-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T19:08:32Z","timestamp":1581016112000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-04674-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["4674"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-04674-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2019,2,7]]},"assertion":[{"value":"20 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors have nothing to declare regarding this work. Dr. Saji reports grants and personal fees from Eisai, grants and personal fees from Chugai, grants and personal fees from AstraZeneca, grants and personal fees from Takeda, grants and personal fees from Novartis, grants and personal fees from Taiho, grants and personal fees from Nihon Kayaku, grants from Ono, personal fees from KyowaHakko-Kirin, personal fees from Pfizer, and personal fees from Daiichi Sankyo, outside the submitted work. Dr. Ohno reports grants and personal fees from Chugai, grants and personal fees from Taiho, grants and personal fees from Eisai, grants from Daiichi Sankyo, personal fees from AstraZeneca, personal fees from KyowaHakko-kirin, personal fees from Pfizer, and personal fees from Novartis, outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}